Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization

Investigative Ophthalmology and Visual Science

Volumn 38, Issue 10, 1997, Pages 1954-1962

  BenEzra, David ^a   Griffin, Brenda W ^b   Maftzir, Genia ^b   Sharif, Najam A ^b   Clark, Abbot F ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b ALCON RESEARCH LTD   (United States)

Author keywords

AL 3789 ophthalmic formulation; Angiostatic steroid; Lipopolysaccharide; Neovascularization inhibitor; Rabbit corneal neovascularization

Indexed keywords

AL 4940; ANECORTAVE; ANGIOGENESIS INHIBITOR; EYE DROPS; HYDROCORTISONE ACETATE; STEROID; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DOSE RESPONSE; DRUG FORMULATION; EDEMA; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; TOPICAL DRUG ADMINISTRATION; WOUND HEALING;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; CORNEA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; FEMALE; HYDROCORTISONE; LIPOPOLYSACCHARIDES; MALE; OPHTHALMIC SOLUTIONS; POLYVINYLS; RABBITS; SALMONELLA TYPHIMURIUM;

EID: 0030955337     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Michaelson IC. The mode of development of the retinal vessels and some observations of its significance in certain retinal diseases. Trans Ophthalmol Soc UK. 1948;68:137-180.
2. Patten BM. Foundations of Embryology. 2nd ed. New York: McGraw-Hill; 1964.
3. Klintworth GK. Corneal Angiogenesis. A Comprehensive Critical Review. New York: Springer-Verlag; 1991.
4. Reynolds LP, Killilea SD, Redmmer DA. Angiogenesis in the female reproductive system. FASEB J. 1992; 6:886-892.
5. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992; 267:10931-10934.
6. BenEzra D. Neovasculogenic ability of prostaglandins, growth factors, and synthetic chemoattractants. Am J Ophthalmol. 1978;4:455-461.
7. BenEzra D. Neovasculogenesis: Triggering factors and possible mechanisms. Sum Ophthalmol. 1979;24:167-176.
8. Raymond L, Jacobson B. Isolation and identification of stimulatory and inhibitory cell growth factors in bovine vitreous. Exp Eye Res. 1982;34:267-286.
9. Gospodarowicz D, Bialecki H, Thakral TK. The angiogenic activity of the fibroblast and epidermal growth factor. Exp Eye Res. 1979;28:501-514.
10. Oikawa T, Hirotani K, Nakamura O, Shudo K, Hiragun A, Iwaguchi T. A highly potent antiangiogenic activity of retinoids. Cancer Lett. 1989;48:157-162.
11. Maione TE, Gray GS, Petro J, et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science. 1990;247:77-79.
12. Moses MA, Sudhalter J, Langer R. Identification of an inhibitor of neovascularization from cartilage. Science. 1990;248:1408-1410.
13. BenEzra D. Clinical ocular angiogenesis. In: Maragoudakis ME, ed. Angiogenesis: Molecular Biology, Clinical Aspects. New York: Plenum Press; 1994:272-282.
14. Ingber DE, Madri JA, Folkman J. A possible mechanism for inhibition of angiogenesis by angiostatic steroids: Induction of capillary basement membrane dissolution. Endocrinology. 1986;119:1768-1775.
15. BenEzra D, Maftzir G. Inhibition of neovascular stimuli. In: BenEzra D, Ryan SJ, Glaser B, Murphy R, eds. Ocular circulation and neovascularization. Documenta Ophthalmologica Proceedings Series 50. Dordrecht, The Netherlands: Martinus Nijhoff; 1987:335-340.
16. Avery RL, Connor TB, Fanazdaghi M. Systemic amiloride inhibits experimentally induced neovascularization. Arch Ophthalmol. 1990;108:1474-1476.
17. Maione TE, Sharpe RJ. Development of angiogenesis inhibitors for clinical trials. Trends Pharmacol Sci. 1990; 11:457-461.
18. Jaakkola A, Antilla PM, Immonen I. Interferon alpha-2α in the treatment of exudative senile macular degeneration Acta Ophthalmol Scand, 1994;72:545-549.
19. Langer R, Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature. 1976;263:797-800.
20. BenEzra D, Hemo I, Maftzir G. The rabbit cornea. A model for the study of angiogenic factors. In: BenEzra D, Ryan SJ, Glaser B, Murphy R, eds. Ocular circulation and neovascularization. Documenta Ophthalmologia Proceedings Series 50. Dordrecht, The Netherlands: Martinus Nijhoff; 1987:335-340.
21. BenEzra D, Griffin BW, Maftzir G, Aharonov O. Thrombospondin and in vivo angiogenesis induced by basic fibroblast growth factor or lipopolysaccharide. Invest Ophthalmol Vis Sci. 1993;43:3601-3608.
22. Michaelson IC. Effect of cortisone upon cornea vascularization produced experimentally. Arch Ophthalmol. 1952;47:459-464.
23. BenEzra D. Neovascularization. A Unitarian phenomenon. Doc Ophthalmol. 1981;25:125-131.
24. Nikolic L, Friend J, Taylor S, Thoft RA. Inhibition of vascularization in rabbit corneas by heparin: Cortisone pellets. Invest Ophthalmol Vis Sci. 1986;27:449-456.
25. Folkman J, Ingber DE. Angiostatic steroids. Method of discovery and mechanism of action. Ann Surg. 1987; 206:374-383.
26. Li WW, Casey R, Gonzalez EM, Folkman J. Angiostatic steroids potentiated by sulfated cyclodextrins inhibit corneal neovascularization. Invest Ophthalmol Vis Sci. 1991;32:2898-2905.
27. Polansky J, Weinreb RN. Anti-inflammatory agents. Steroids as anti-inflammatory agents. In: Sears ML, ed. Handbook of Experimental Pharmacology. Vol. 69. Berlin: Springer-Verlag; 1984:459-538.
28. Cantrill HL, Palmberg PF, Zink HA, Waltman SR, Podos SM, Becker B. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol, 1975;79:1012-1017.
29. Clark AF. Steroids, ocular hypertension, and glaucoma. J Glaucoma. 1995;4:354-369.
30. Clark AF, McNatt L, Knepper PA. Angiostatic steroids as a new class of IOP lowering compounds, ARVO Abstracts. Invest Ophthalmol Vis Sci. 1994;35:1483.
31. Tolman BL, Collier RJ, Clark AF, Penn JS. Effects of an angiostatic steroid on neovascularization in the rat model of ROP. ARVO Abstracts. Invest Ophthalmol Vis Sci. 1995;36:S93.
32. Ma D, Clark AF, Alizadeh H, Mellon J, Niederkom JY. Inhibition of intraocular tumor growth by topical application of the angiostatic agent AL-3789. ARVO Abstracts. Invest Ophthalmol Vis Sci. 1995;36:S489.
33. Ashino-Fuse H, Takano Y, Oikawa T, Shimamura M, Iwaguchi T. Medroxyprogesterone acetate, an anticancer and anti-angiogenic steroid, inhibits the plasminogen activator in bovine endothelial cells. Int J Cancer. 1989;44:859-864.
34. Pepper MS, Vassalli J-D, Wilks JW, Schweigerer I., Orci L, Montesano R. Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J Cell Biochem. 1994;55:419-434.
35. Blei F, Wilson EL, Magnatti P, Rifkin DB. Mechanism of action of angiostatic steroids: Suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol. 1993; 115:568-578.